NCT07218250 A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Breast Cancer
| NCT ID | NCT07218250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2026-06-04 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2026-06-04 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see if a Single Counseling Session for Cancer can help reduce psychosocial distress and improve quality of life in people with breast cancer who are waiting to receive ongoing counseling services (outpatient psychotherapy services). The Single Counseling Session for Cancer-which I will refer to as the "study counseling" during this call-is a one-session, 60-minute counseling program designed to reduce anxiety and depression symptoms in people with cancer who are waiting to receive outpatient psychotherapy services. The researchers will look at whether the study counseling is effective in participants and practical (feasible) for them to complete.
Eligibility Criteria
Inclusion Criteria: * Patient must have pathologically confirmed breast cancer (per EMR). * Patient with localized or advanced cancer (per EMR). * Patient is on a waitlist of at least 2 weeks or more for MSK Counseling Center intake and will not complete a New Visit with a clinical psychologist prior to intervention (these patients will be replaced) (per EMR, patient's care team, or self-report) * Has not had and is not scheduled to have an appointment with an MSK psychiatrist or MSK Counseling Center advanced practice provider (per EMR, patient's care team, or self-report) * Female (per EMR) * Age ≥ 18 (per EMR) * English fluency - Per self-report: How well do you speak English? * Agrees to be audio-recorded (per self-report) NOTE: Participants who report Very well are considered fluent. * Lives in New York, New Jersey, Connecticut, or Florida (per self-report). * Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require urgent or extended individual treatment) (per EMR, patient's care team, or study team). * Has no presence of cognitive impairment disorder (i.e., delirium, dementia, or traumatic brain injury) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, study team, or per self-report of BOMC cognitive test). * Has no current active or passive suicidal ideation ((per EMR, patient's care team, study team, per item 9 of the PHQ-9, or the CSSRS).
Contact & Investigator
Devika Jutagir, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07218250 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07218250 currently recruiting?
Yes, NCT07218250 is actively recruiting participants. Contact the research team at jutagird@mskcc.org for enrollment information.
Where is the NCT07218250 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07218250 clinical trial?
NCT07218250 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Devika Jutagir, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 26 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.